This is a strong insider conviction buy at the same price as the offering, suggesting insiders view the post-dilution stock as undervalued. The $125M capital raise provides a multi-year cash runway for clinical programs, removing near-term financing overhang. Monitor for additional insider buying and upcoming clinical data readouts for CR-001/CR-002/CR-003 as potential catalysts.
Price Chart
Executive Summary
Director and 10% owner Fairmount Funds Management LLC made a $12.38M open-market purchase of 853,450 CBIO shares at $14.50 on July 16, 2026, the same day as a $125M dilutive offering closed. This insider buy partially offsets the bearish signal from the offering, signaling insider confidence in the company's valuation post-dilution. The purchase represents ~2.4% of market cap, a highly material insider buy that typically predicts positive forward returns.
Key Financial Metrics
Key Facts
- Director/10% owner Fairmount Funds purchased 853,450 shares at $14.50 for $12.38M on July 16, 2026
- Purchase equals ~2.4% of CBIO's $526M market cap, a highly material insider buy
- Buy occurred on same day as $125M dilutive offering closed, signaling insider confidence in post-dilution value
- Fairmount also purchased 525,897 pre-funded warrants at $14.499 for $7.62M on the same day
- Total insider buying in last 30 days is $20M vs only $1.2M in insider sales
Financial Impact
Insider purchase of $12.38M represents ~2.4% of market cap; combined with pre-funded warrant purchase totals ~$20M or ~3.8% of market cap
Risk Factors
- Clinical-stage biotech with no revenue; pipeline failure risk remains high
- Dilution from the $125M offering adds ~8.6M shares (plus warrants) to the float
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0001104659-26-085113 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 8-K | $11.84 | awaiting T+60 | — | $12.76 (+7.77%) |
Oct 15, 2026 12d ago | Press Release | $11.84 | awaiting T+60 | — | $12.76 (+7.77%) |
Oct 5, 2026 22d ago | Press Release | $13.94 | awaiting T+60 | — | $12.76 (−8.46%) |
Sep 18, 2026 5w ago | Insider Cluster | $16.25 | awaiting T+60 | — | $12.76 (−21.48%) |
Jul 30, 2026 12w ago | 8-K | $15.02 $12.82 | ▼ −14.65% | ▼ −17.11% | $12.76 (−15.05%) |
Jul 20, 2026 14w ago | Insider Buy | $16.64 $12.91 | ▼ −22.42% | ▼ −26.39% | $12.76 (−23.32%) |
Jul 15, 2026 14w ago | 8-K / 424B5 | $15.11 $14.91 | ▲ +1.32% | ▲ +5.03% | $12.76 (+15.55%) |
Jul 14, 2026 14w ago | Press Release | $15.67 $14.12 | ▲ +9.89% | ▲ +12.42% | $12.76 (+18.57%) |
Jul 14, 2026 15w ago | 424B5 | $15.67 $14.12 | ▲ +9.89% | ▲ +12.42% | $12.76 (+18.57%) |
Jul 13, 2026 15w ago | EFFECT | $15.69 $13.57 | ▼ −13.51% | ▼ −17.51% | $12.76 (−18.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers